Trial Profile
AN OPEN STUDY OF LAMIVUDINE TREATMENT IN ADULT HBeAg NEGATIVE (Presumed Pre-core Mutant) CHRONIC HEPATITIS B PATIENTS IN IRAN.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Lamivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; ViiV Healthcare
- 28 Feb 2020 Status changed from active, no longer recruiting to completed.
- 29 Sep 2006 New trial record.